实验室诊断技术在耐药结核病中应用价值的若干思考

doi:10.3969/j.issn.2096-8493.2021.01.004

摘要/Abstract

摘要：

耐药结核病仍是结核病防控的重要挑战。近年兴起的分子生物学诊断方法克服了传统耐药诊断方法的不足,提高了其在临床应用中的价值,但是如何更好地利用分子生物学诊断方法服务于临床是值得思考的问题。作者主要系统分析了现有耐药结核病诊断技术,梳理了分子耐药检测技术在临床使用存在的困境,以期对医务工作者有所启发,并为耐药结核病的诊治提供参考。

关键词: 抗药性, 细菌, 分枝杆菌, 结核, 微生物敏感性试验, 分子诊断技术

Abstract:

Drug-resistant tuberculosis remains an important challenge for TB control. The recent development of molecular biology diagnostics overcomes the shortcomings of traditional drug-resistance diagnosis methods, which has increased its value in clinical applications, but how to make better use of molecular biological diagnostic methods for clinical service is worth to be considered. In this paper, the authors systematically analyze the current diagnostics for drug-resistant tuberculosis, and summarize the dilemmas in the clinical use of molecular diagnostics for detection of drug resistance tuberculosis, aiming to provide important clinical experience for the diagnosis and treatment of drug-resistant tuberculosis.

Key words: Drug resistance, bacterial, Mycobacterium tuberculosis, Microbial sensitivity tests, Molecular diagnostic techniques

张治国, 郭海萍, 逄宇. 实验室诊断技术在耐药结核病中应用价值的若干思考[J]. 结核与肺部疾病杂志, 2021, 2(1): 13-17. doi: 10.3969/j.issn.2096-8493.2021.01.004

ZHANG Zhi-guo, GUO Hai-ping, PANG Yu. Considerations for the application of laboratory diagnostics in detecting drug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 13-17. doi: 10.3969/j.issn.2096-8493.2021.01.004

参考文献 36

[1]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[2]	刘斌, 刘君, 裴豪, 等. 结核分枝杆菌实验室及其药敏检测技术进展. 中华医院感染学杂志, 2020,30(15):2396-2400. doi: 10.11816/cn.ni.2020-191954.
[3]	Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis, 2013,13(5):449-458. doi: 10.1016/S1473-3099(13)70025-2. doi: 10.1016/S1473-3099(13)70025-2 URL
[4]	王丽娜. 痰液结核杆菌涂片及培养在初诊结核病中的应用比较. 罕少疾病杂志, 2019,26(5):19-21. doi: 10.3969/j.issn.1009-3257.2019.05.008.
[5]	Kelly-Cirino CD, Musisi E, Byanyima P, et al. Investigation of OMNIgene·SPUTUM performance in delayed tuberculosis testing by smear, culture, and Xpert MTB/RIF assays in Uganda. J Epidemiol Glob Health, 2017,7(2):103-109. doi: 10.1016/j.jegh.2017.04.001. doi: 10.1016/j.jegh.2017.04.001 URL pmid: 28413105
[6]	徐成良, 陈兆俊, 陆英, 等. 结核分枝杆菌两种培养方法比较. 上海预防医学, 2016,28(8):563-564. doi: 10.19428/j.cnki.sjpm.2016.08.016.
[7]	李仁忠, 王黎霞. 实验室新技术用于耐药结核病诊断流程的建议. 中华结核和呼吸杂志, 2016,39(7):568-569. doi: 10.3760/cma.j.issn.1001-0939.2016.07.020.
[8]	刘金娜. 微量液体培养基最低抑菌浓度法与罗氏比例法在结核分枝杆菌药敏试验中的价值比较. 实用临床医药杂志, 2020,24(17):28-30,40. doi: 10.7619/jcmp.202017007.
[9]	逄宇, 王玉峰, 高兴辉, 等. 结核分枝杆菌实验室检测产品和技术应用进展. 中国临床新医学, 2021,14(1):23-34. doi: 10.3969/j.issn.1674-3806.2021.01.05.
[10]	Harries AD, Kumar AMV. Challenges and Progress with Diagnosing Pulmonary Tuberculosis in Low- and Middle-Income Countries. Diagnostics (Basel), 2018,8(4):78. doi: 10.3390/diagnostics8040078.
[11]	赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 88-105.
[12]	Chauhan DS, Sharma R, Parashar D, et al. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis in clinical spe-cimens by real-time po8lymerase chain reaction hybridisation probe method. Indian J Med Microbiol, 2018,36(2):211-216. doi: 10.4103/ijmm.IJMM_14_304. doi: 10.4103/ijmm.IJMM_14_304 URL pmid: 30084413
[13]	饶兵. 线性探针技术在耐药结核病诊断中的应用. 东方药膳, 2020 (8):35.
[14]	刘立宾, 王静, 李浩, 等. 三种分子方法检测结核分枝杆菌利福平耐药性的比较. 中华临床感染病杂志, 2020,13(4):270-275. doi: 10.3760/cma.j.issn.1674-2397.2020.04.004.
[15]	MacLean E, Kohli M, Weber SF, et al. Advances in Molecular Diagnosis of Tuberculosis. J Clin Microbiol, 2020,58(10):e01582-19. doi: 10.1128/JCM.01582-19. doi: 10.1128/JCM.01582-19 URL pmid: 32759357
[16]	Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med, 2015,3(6):451-461. doi: 10.1016/S2213-2600(15)00095-8. doi: 10.1016/S2213-2600(15)00095-8 URL pmid: 25812968
[17]	Jeyashree K, Shanmugasundaram D, Rade K, et al. Impact and operational feasibility of TrueNat^TM MTB/Rif under India's RNTCP . Public Health Action, 2020,10(3):87-91. doi: 10.5588/pha.20.0004. doi: 10.5588/pha.20.0004 URL pmid: 33134121
[18]	Nikam C, Jagannath M, Narayanan MM, et al. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PLoS One, 2013,8(1):e51121. doi: 10.1371/journal.pone.0051121. doi: 10.1371/journal.pone.0051121 URL pmid: 23349670
[19]	Nikam C, Kazi M, Nair C, et al. Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. Int J Mycobacteriol, 2014,3(3):205-210. doi: 10.1016/j.ijmyco.2014.04.003. doi: 10.1016/j.ijmyco.2014.04.003 URL pmid: 26786489
[20]	Ciesielczuk H, Kouvas N, North N, et al. Evaluation of the BD MAX^TM MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB. Eur J Clin Microbiol Infect Dis, 2020,39(7):1321-1327. doi: 10.1007/s10096-020-03847-2. doi: 10.1007/s10096-020-03847-2 URL pmid: 32078067
[21]	Hofmann-Thiel S, Plesnik S, Mihalic M, et al. Clinical Evaluation of BD MAX MDR-TB Assay for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers. J Mol Diagn, 2020,22(10):1280-1286. doi: 10.1016/j.jmoldx.2020.06.013. doi: 10.1016/j.jmoldx.2020.06.013 URL pmid: 32688054
[22]	徐东芳, 王超, 包训迪, 等. 线性探针技术在耐药结核病诊断中的应用. 安徽医药, 2020,24(12):2422-2425. doi: 10.3969/j.issn.1009-6469.2020.12.023.
[23]	Brandao AP, Pinhata JMW, Oliveira RS, et al. Speeding up the diagnosis of multidrug-resistant tuberculosis in a high-burden region with the use of a commercial line probe assay. J Bras Pneumol, 2019,45(2):e20180128. doi: 10.1590/1806-3713/e20180128. doi: 10.1590/1806-3713/e20180128 URL pmid: 31017225
[24]	Sharma K, Sharma M, Shree R, et al. Xpert MTB/RIF ultra for the diagnosis of tuberculous meningitis: A diagnostic accuracy study from India. Tuberculosis (Edinb), 2020,125:101990. doi: 10.1016/j.tube.2020.101990. doi: 10.1016/j.tube.2020.101990 URL
[25]	Horne DJ, Kohli M, Zifodya JS, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev, 2019, 6(6):CD009593. doi: 10.1002/14651858.CD009593.pub4.
[26]	赵国连, 崔晓利, 康磊, 等. 荧光PCR探针熔解曲线技术检测涂阳患者痰标本中结核分枝杆菌耐药性的价值. 中国防痨杂志, 2019,41(2):149-155. doi: 10.3969/j.issn.1000-6621.2019.02.006.
[27]	Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep, 2016,6:25330. doi: 10.1038/srep25330. doi: 10.1038/srep25330 URL pmid: 27149911
[28]	Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet, 2011,43(5):482-486. doi: 10.1038/ng.811. doi: 10.1038/ng.811 URL pmid: 21516081
[29]	Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med, 2015,7(1):51. doi: 10.1186/s13073-015-0164-0. doi: 10.1186/s13073-015-0164-0 URL pmid: 26019726
[30]	Gygli SM, Keller PM, Ballif M, et al. Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019,63(4):e02175-18. doi: 10.1128/AAC.02175-18. doi: 10.1128/AAC.02175-18 URL pmid: 30718257
[31]	Cohen KA, Manson AL, Desjardins CA, et al. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med, 2019,11(1):45. doi: 10.1186/s13073-019-0660-8. doi: 10.1186/s13073-019-0660-8 URL pmid: 31345251
[32]	Lee M, Mok J, Kim DK, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase Ⅱ/Ⅲ, multicenter, randomized, open-label clinical trial. Trials, 2019,20(1):57. doi: 10.1186/s13063-018-3053-1. doi: 10.1186/s13063-018-3053-1 URL pmid: 30651149
[33]	Sharma N, Singla N, Khanna A, et al. Pattern and trends of drug sensitivity in MDR-TB cases in Delhi (2009—2014): A record based study. Indian J Tuberc, 2019,66(2):222-226. doi: 10.1016/j.ijtb.2019.02.017. doi: 10.1016/j.ijtb.2019.02.017 URL pmid: 31151488
[34]	World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization, 2018.
[35]	Schön T, Miotto P, Köser CU, et al. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect, 2017,23(3):154-160. doi: 10.1016/j.cmi.2016.10.022. doi: 10.1016/j.cmi.2016.10.022 URL pmid: 27810467
[36]	World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. Geneva: World Health Organization, 2021.